Objectives and Design: In this study, we examined the role of MALAT1, a highly conserved nuclear long non-coding RNA molecule, in chronic diabetic complications affecting the heart and kidneys using both in vitro and in vivo models: human endothelial cell culture and a Malat1 knockout mice model.
receptors are activated, downstream signalling cascades are evoked to further stimulate the production of inflammatory cytokines and extracellular matrix proteins that promote a pro-inflammatory environment, thereby resulting in inflammatory-mediated damage to the affected tissues. 8, 9 At the transcriptional level, regulating the production of downstream transcriptional factors is a major mechanism in the genesis of downstream effects. 10, 11 We have previously shown that alterations in epigenetic modifications such as histone acetylation and specific microRNAs (miRs) can affect this transcriptional regulation and mediate glucose-induced abnormalities. 12, 13 Nevertheless, the transcriptional process can also be controlled by long noncoding RNAs (lncRNAs). 14 LncRNAs are >200 nucleotides in length and generally do not code for proteins. 14, 15 Despite possessing little or no protein-coding capabilities, lncRNAs are still capable of regulating protein and non-proteincoding genes through both cis-and trans-acting effects. 15 LncRNA MALAT1 (metastasis-associated lung adenocarcinoma transcript 1, also known as NEAT2) was first identified in early-stage non-small-cell lung carcinoma cells. 16 MALAT1 encodes an 8.7-kb exonic transcript that has high levels of transcription in many tissues including the heart, kidney and brain. 17, 18 MALAT1 is highly conserved among mammals; however, particular conserved regions of MALAT1 have been found in other species such as frogs and fish. 19, 20 MALAT1 is primarily retained in the nucleus, where it associates with other molecules in nuclear speckles and has been shown to regulate gene transcription. 21, 22 The definitive roles of lncRNAs in DM remain largely elusive; however, studies have indicated that lncRNAs may be implicated in β-cell function, 23, 24 glucose homeostasis, 25 end-stage kidney disease 26 and endothelial cell dysfunction. 27 Earlier work completed by our laboratory showed for the first time that MALAT1 expression is elevated in large vessel endothelial cells (human umbilical vein endothelial cells; HUVECs)
following high glucose incubation in vitro. 28 Furthermore, the increase in MALAT1 transcript expression correlated with increases in multiple inflammatory proteins (IL-6 and TNF-α) and siRNA-mediated MALAT1 knockdown subsequently prevented the upregulation of glucoseinduced inflammatory cytokines. 28 To further confirm our previous findings, a recent study has shown that TNF-α expression in splenocytes was lower in mice lacking MALAT1 compared to wild-type (WT) mice. 29 Although MALAT1 is thought to be associated with the generation of pro-inflammatory cytokines, 27, 28, 30 use of a novel Malat1 knockout (KO) mice model will provide the opportunity to demonstrate a direct causal relationship between MALAT1 and the inflammatory network.
Mouse knockout models of Malat1 have been generated previously that remove either portions or the entire gene segment of Malat1.
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These knockouts are not only nonlethal, but also show no observable phenotype. 21, 22 32 Despite the revelations from these reports, whether similar patterns exist in the diabetic heart and kidneys after Malat1 KO still remains unclear.
In this study, we investigated the regulatory role of MALAT1 on the expression of inflammatory cytokines and subsequent structural and functional effects in the diabetic heart and kidneys using a Malat1 knockout mice model with chronically induced diabetes as well as in a cell culture system using microvascular endothelial cells.
| MATERIALS AND METHODS

| Animal experiments
Mice with a homozygous deletion in the Malat1 gene (Malat1 KO) were obtained through collaboration with Dr. 34 In addition to our in vitro work with HRECs, we cultured human cardiac microvascular endothelial cells (HCMECs;
purchased from Olaf Pharmaceuticals) in high glucose to determine the MALAT1 RNA expression levels at multiple time points ( Figure S1 ).
| Cardiac imaging
Echocardiographic and Doppler studies were performed using the Vevo™ 2100 imaging system (Visualsonic, Toronto, ON, Canada). All examinations were performed 1 week prior to the time of sacrifice between 1 pm and 5 pm. Each mouse was anesthetized in a sealed chamber with inhalant isoflurane at 3% in 100% oxygen. Once anesthetized, the mouse was transferred and secured on its dorsal side to a heated imaging platform and isoflurane was maintained at 1% for the duration of the experiment. The hair on the mouse chest was carefully removed to reduce signal attenuation, and an electrode gel was applied to the chest before placing the transducer to the left of the sternum. At this position, images were obtained of the left ventricle along its long axis. The blood flow velocity was measured using Doppler ultrasonography to directly measure the flow motion (Pulse Wave Doppler). M-mode tracings of the heart were acquired by rotating the transducer to be perpendicular to the left ventricle and aligned along the short axis of the heart.
Measurements were averaged from 3 consecutive cardiac cycles. Gene-specific primer sets were designed using the basic local alignment program (BLAST) from NCBI, or predesigned sets were ordered from Qiagen (Toronto, ON, Canada) (Table S1 ). Target genes were analysed using standard curves to determine relative levels of gene expression. The levels of specific RNAs were analysed using the Roche LightCycler™ 96
System. Individual RNA samples were normalized to the level of β-actin. 
| RNA in situ hybridization
RNA fluorescent in situ hybridization (FISH) was carried out using specific probes and reagents designed by Stellaris™ RNA FISH (Biosearch 
| Statistical analysis
All experimental data are expressed as mean ± SEM. Student's t test was used when comparing 2 conditions, whereas ANOVA, followed by Tukey's post hoc test, was employed when comparing multiple conditions. A P value of <5% (P < .05) was considered statistically significant.
| RESULTS
| High glucose leads to increased endothelial production of MALAT1, which is associated with increased pro-inflammatory transcripts
Endothelial cells are primary targets of glucose-induced alterations due to their location and function as the proximal barrier to blood. Considering these characteristics, we examined microvascular endothelial cells cultured under normal (5 mmol/L; NG) or high glucose conditions (25 mmol/L; HG) to evaluate MALAT1 expression.
Our initial experiments showed that MALAT1 expression peaks after 48 hours of HG incubation; hence, we used this time point for all of our in vitro experiments. We found that at 48 hours, both MALAT1
and RNA transcripts coding for pro-inflammatory cytokines (TNF-α, Figure 1E ). Furthermore, extending our findings into HCMECs, MALAT1 was significantly elevated at 12 hours following HG incubation-suggesting a cell-specific phenotype for MALAT1 ( Figure S1 ).
| Animal monitoring
As the primary aim of this study was to delineate the role for MALAT1
in the regulation of inflammatory cytokines in tissues affected by hyperglycaemia, we used both WT C57/BL6 mice and Malat1 KO animals with STZ-induced diabetes and nondiabetic controls. Both diabetic WT and KO animals developed hyperglycaemia and had reduced body weight gain compared to the nondiabetic WT and KO mice (Figure 2A,B ). There were no observable differences between WT and KO control animals.
| Diabetes-induced cardiac and kidney inflammatory gene expressions are regulated by MALAT1
With the heart and kidneys being target sites for tissue damage in diabetes, we first wanted to establish the effects of MALAT1 on animal hearts and kidneys affected by diabetes. Control and diabetic mice were sacrificed at 5 time points over 2 months following the onset of diabetes (0, 1, 2, 4 and 8 weeks). We found that MALAT1 expression levels in heart and kidney tissues of WT diabetic animals were initially elevated more than threefold at 1 week when compared to WT nondiabetic animals. However, expression levels of MALAT1 in the WT diabetic animals decreased after 1 week and remained at this level for To further examine whether this early increase in MALAT1 might be a result of the STZ, we implemented a metabolic model of hyperhexosemia using a custom diet high in galactose, where mice fed this custom diet were compared to mice on a standard diet-we have used this approach in the past. 38, 39 We found that 1 week of galactose feeding led to significantly elevated levels of MALAT1 in heart and kidney tissues compared to age-and gender-matched mice that were fed a standard diet ( Figure 2E ,F).
| MALAT1 regulates increased levels of inflammatory cytokines in the heart during diabetes
We examined pro-inflammatory cytokines (IL-1β, IL-6, TNF-α and IFN-λ) in mice cardiac tissues at 1 and 2 months postonset of diabetes Increased MALAT1 RNA expressions were also seen in the (E) hearts and (F) kidneys of diabetic animals following 1 week of galactose feeding ("Galactose Fed") (*P < 0.05 compared to WT-Co or Control Fed; n = 8 or more/group; data expressed as mean ± SEM; normalized to β-actin; and expressed as a fold change in WT-Co or Control Fed) ( Figure 3 ). WT diabetic animals had significantly elevated levels of pro-inflammatory transcripts at both time points compared to controls. Interestingly, we found that diabetic KO animals had significantly lower levels of these transcripts. These levels were similar to the baseline levels found in control animals. No significant differences were found between WT control and KO control animals. We further expanded the study and examined protein levels of IL-6 and INF-γ in the hearts of WT and Malat1 KO mice. Diabetes caused upregulation of IL-6 and IFN-λ protein levels in WT diabetic animals; however, such changes were absent in diabetic Malat1 KO animals ( Figure 4A ,B).
| Loss of MALAT1 reduced cardiac dysfunction postdiabetes
We also examined whether such RNA and protein changes affected cardiac function. Hence, we analysed echocardiographic data from 2-month diabetic animals at the time of sacrifice. Both nondiabetic Malat1 KO and WT control animals showed normal E/A ratios. In contrast, WT diabetic animals had significantly decreased E/A ratios, indicating diastolic dysfunction. Diabetic Malat1 KO animals had a partial protective effect on diabetes-induced cardiac dysfunction ( Figure 4C,D) . No significant differences in heart rates were observed between all groups (Table S2 ).
| Loss of MALAT1 protects against increased levels of inflammatory cytokines in the kidneys during diabetes
Similarly, we examined renal tissues for changes in cytokines at the mRNA and protein levels after 1 and 2 months of follow-up. We found that these cytokine transcripts (IL-1β, IL-6, TNF-α and IFN-λ)
were elevated in renal tissues from WT diabetic animals. However, such elevations in RNA and protein levels were prevented in diabetic KO animals at both time points ( Figures 4E-G and 5 ). To assess renal 
| DISCUSSION
Our current study demonstrated that the lncRNA MALAT1 regulates inflammatory cytokine production in diabetes. We have demonstrated such regulation in endothelial cells, the primary target of glucoseinduced vascular damage, as well as the kidneys and heart in diabetes. Furthermore, we have shown that such changes and subsequent organ dysfunction in diabetes are prevented in Malat1 KO mice.
It has been previously established that secondary to sustained hyperglycaemia in diabetes, persistent low-grade inflammatory processes resulting from increased cytokine expression leads to cellular insult, tissue injury and functional impairments. 9, 40, 41 This study delineates a novel mechanism mediating such processes at the transcriptional level. Our study further implies that the nuclear-retained lncRNA MALAT1 is a regulator of these cytokines during hyperglycaemic conditions.
Extending the findings from our previous MALAT1 study, here, we targeted the heart and kidneys because both organs are substantially affected by diabetes and highly express MALAT1. 17, 18, 28, 42 We examined the mechanisms at various levels of complexities, using microvascular endothelial cells, and then translated our in vitro work to an animal model. In keeping with previous studies, 48, 49 we found that MALAT1 is localized to nuclear speckles in endothelial cells. Interestingly, premRNA splicing factors are also localized in these nuclear domains, which may allude to other implications of MALAT1 in nuclear organization. 50 Although the exact mechanism of glucose-induced regulation of MALAT1 remains to be deciphered, it may be regulated epigenetically through its association with Polycomb repressive complex 2. 51 Intriguingly, we have previously shown glucose-induced alterations of miRs and another lncRNA through such pathways. 43, 52 It is of further interest to note that other substrates (eg fatty acids) may also change MALAT1 expression. 53 Relationships of such alterations, with respect to chronic diabetic complications, need additional exploration and may uncover novel links between MALAT1 function and pathological processes. Moreover, this study has shown that although MALAT1 upregulation was seen after 1 week of high glucose incubation, the initial increase in MALAT1 showed long-lasting effects.
Most probably, this can be explained by the "metabolic memory" phenomenon. In keeping with this theory, El-Osta et al 54 have previously
shown that transient hyperglycaemia can lead to long-term histone methylation alterations and transcription factor activation. However, we do recognize that additional experiments are needed to confirm this notion. No changes in expressions were observed in the KO-Co and WT-Co animals (*P < .05 compared to WT-Co, #P < .05 compared to WT-D; n = 6/group; data expressed as mean ± SEM; normalized to β-actin; and expressed as a fold change in WT-Co)
Our findings, in general, show that MALAT1 is an important contributor to increased levels of inflammatory cytokines in diabetic mice at 1 and 2 months. As observed from our diabetic KO group, globally eliminating Malat1 had a significant impact on inflammatory cytokines at 1 and 2 months-suggesting that MALAT1 may have a role in inflammatory regulation during diabetes. Furthermore, Hu et al 32 have recently suggested that early high glucose-induced increases of MALAT1 may be capable of activating and sustaining splicing patterns for certain pre-mRNAs, as well as potentially activating a degradation mechanism that "overcorrects" the MALAT1 expression at later time points. Interestingly, a similar phenomenon was observed in our cardiac endothelial cells exposed to HG ( Figure S1 ) and diabetic animal kidney and heart tissues ( Figure 2C,D Hence in future studies, conducting cell-specific experiments for these tissues may help to elucidate the function of MALAT1 in these organs and the cells that comprise them. In this study, we report that the loss of MALAT1 eliminates the increased production of inflammatory cytokines that is typical of diabetes in both cardiac and renal tissues. We also demonstrated in vivo that the loss of MALAT1 is protective against cardiac dysfunction, which is observed in diabetes.
Nevertheless, this is the first study to use a chronically diabetic KO animal model to examine MALAT1 in mediating cardiac and renal damage. In accordance with past findings, 30, 31 our study demonstrates that MALAT1 plays a significant role in mediating diabetes-induced tissue damage through regulation of the inflammatory process. Using a wellestablished model of type 1 diabetes, our research provides direct evidence that MALAT1 plays a pathogenetic role in chronic diabetic complications affecting the heart and kidneys. Establishing this link between lncRNAs and diabetes opens the door for novel RNA-based therapeutic targets. However, it becomes important to recognize that there are other epigenetic mechanisms (eg histone methylation and acetylation, and the activity of miRs) in play that may modulate such processes. 44 Furthermore, in the current context, whether epigenetic mechanisms observed here can lead to permanent alterations require additional investigation. 59 Well-designed long-term studies are needed to address such questions and improve our understanding of lncRNAs and their functions.
